Segall Bryant & Hamill LLC Increases Stock Position in QuidelOrtho Corporation $QDEL

Segall Bryant & Hamill LLC boosted its holdings in QuidelOrtho Corporation (NASDAQ:QDEL) by 0.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,300,196 shares of the company’s stock after purchasing an additional 11,478 shares during the quarter. Segall Bryant & Hamill LLC owned about 1.91% of QuidelOrtho worth $37,472,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Clear Harbor Asset Management LLC increased its holdings in shares of QuidelOrtho by 147.5% in the second quarter. Clear Harbor Asset Management LLC now owns 34,186 shares of the company’s stock valued at $985,000 after purchasing an additional 20,374 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of QuidelOrtho during the first quarter worth $411,000. Nordea Investment Management AB purchased a new position in QuidelOrtho in the 2nd quarter valued at $2,609,000. Lightrock Netherlands B.V. increased its stake in QuidelOrtho by 27.8% in the 2nd quarter. Lightrock Netherlands B.V. now owns 466,000 shares of the company’s stock valued at $13,430,000 after buying an additional 101,423 shares during the period. Finally, Brighton Jones LLC acquired a new stake in shares of QuidelOrtho in the 2nd quarter worth $384,000. Institutional investors and hedge funds own 99.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a report on Friday, November 7th. UBS Group lifted their price objective on QuidelOrtho from $26.00 to $31.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Wall Street Zen downgraded QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Saturday, July 26th. Zacks Research downgraded QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $38.20.

Insider Buying and Selling

In other QuidelOrtho news, CEO Brian J. Blaser bought 23,500 shares of the company’s stock in a transaction on Wednesday, November 19th. The stock was purchased at an average cost of $21.34 per share, for a total transaction of $501,490.00. Following the acquisition, the chief executive officer owned 29,533 shares of the company’s stock, valued at $630,234.22. The trade was a 389.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.79% of the company’s stock.

QuidelOrtho Stock Performance

QDEL opened at $24.35 on Friday. QuidelOrtho Corporation has a 1-year low of $19.50 and a 1-year high of $49.45. The stock has a market cap of $1.65 billion, a P/E ratio of -3.72 and a beta of 0.35. The stock’s 50 day simple moving average is $26.79 and its 200 day simple moving average is $27.96. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.12 and a quick ratio of 0.62.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.29. QuidelOrtho had a positive return on equity of 5.29% and a negative net margin of 16.10%.The company had revenue of $699.90 million for the quarter, compared to the consensus estimate of $667.45 million. During the same period in the previous year, the business earned $0.85 earnings per share. QuidelOrtho’s quarterly revenue was down 3.7% compared to the same quarter last year. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. As a group, equities analysts anticipate that QuidelOrtho Corporation will post 2.3 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.